Prévisions

Aucune donnée d'analyste n'est disponible pour cette entreprise.

Actualités Accéder au fil d'actualités

Silo Pharma publishes preclinical Alzheimer data and reports progress on PTSD candidate

Silo Pharma announced the publication of preclinical studies on its Alzheimer drug candidate SPC-14 in the journal Alzheimer’s Research & Therapy, which showed positive effects in a mouse model. At the same time, the company reported positive safety data and ongoing studies for SPC-15 (PTSD) and a Notice of Allowance for an SPC-15 patent; it also received a NASDAQ notice for falling below the minimum bid price requirement. The research was conducted in cooperation with Columbia University, and Silo holds an exclusive license for SPC-14 from Columbia. » Plus sur de.investing.com
Bullet Blockchain announces partnership with Tangem to expand crypto wallet offering

Bullet Blockchain is partnering with Swiss hardware-wallet provider Tangem so Tangem users can access crypto trading and other services via Bullet’s network. The company is also integrating supply-chain solutions from Silo Technologies, emphasizes its patent position for Bitcoin ATMs, and is pursuing a four-pillar growth plan to expand its ATM network in the US. » Plus sur de.investing.com
Silo Pharma successfully completes dosing phase in FDA safety study for PTSD drug

Silo Pharma has completed the dosing phase of a seven-day FDA safety and toxicity study for its PTSD drug candidate SPC-15 and expects results within the next 60 days. The company has also received a patent approval for SPC-15, is working on further preclinical studies, and plans to invest up to $1 million in Bitcoin as part of its treasury reserves. Additionally, Silo Pharma has been notified by NASDAQ of non-compliance with the minimum bid price requirement and has until December 2025 to regain compliance. » Plus sur de.investing.com

Dividendes historiques Dividendes

Tous les indicateurs de dividendes Tous les indicateurs

En 2022, Silo Wellness Aktie a déjà versé 0,0471 € de dividendes. Le dernier versement a eu lieu en mars 2022.

Données financières de l'entreprise

Au cours de la dernière année, Silo Wellness Aktie a réalisé un chiffre d'affaires de 339,66 k € et un bénéfice net de -5,88 M €

(EUR)	2022	YoY
Chiffre d'affaires	339,66 k	226,83 %
Bénéfice brut	124,37 k	153,54 %
Bénéfice net	-5,88 M	9,44 %
EBITDA	-5,87 M	11,42 %

Données fondamentales

Indicateur	Valeur
Capitalisation boursière	1,49 M €
Nombre d'actions	154,48 M
Plus haut/bas sur 52 semaines	0,00963 € - 0,00963 €
Dividendes	Non
Bêta	0,77
Ratio P/E	-0,09
Ratio PEG	0,00
Ratio P/B	-0,10
Ratio P/S	3,33

Profil de l'entreprise

Silo Wellness Inc. ist ein Unternehmen für Psychedelika und Wellness und entwickelt psychedelische Medizin zur Traumabewältigung. Es entwickelt und vertreibt psilocybinfreie funktionelle Pilztinkturen und die Formulierung eines Psilocybin-Nasensprays in Jamaika. Außerdem bietet es ein Portfolio von funktionellen Pilzprodukten an: Psychedelische Wellness-Retreats in Jamaika und Oregon sowie der Anbau von psychedelischen Pilzen und Trüffeln in Jamaika; und die Entwicklung eines Smart Shops in Jamaika. Das Unternehmen war früher als Yukoterre Resources Inc. bekannt und änderte seinen Namen in Silo Wellness Inc. 26. Februar 2021. Der Hauptsitz von Silo Wellness Inc. befindet sich in Toronto, Kanada.